Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Agonism of CD11b reprograms innate immunity to sensitize pancreatic cancer to immunotherapies.

Panni RZ, Herndon JM, Zuo C, Hegde S, Hogg GD, Knolhoff BL, Breden MA, Li X, Krisnawan VE, Khan SQ, Schwarz JK, Rogers BE, Fields RC, Hawkins WG, Gupta V, DeNardo DG.

Sci Transl Med. 2019 Jul 3;11(499). pii: eaau9240. doi: 10.1126/scitranslmed.aau9240.

PMID:
31270275
2.

Development of resistance to FAK inhibition in pancreatic cancer is linked to stromal depletion.

Jiang H, Liu X, Knolhoff BL, Hegde S, Lee KB, Jiang H, Fields RC, Pachter JA, Lim KH, DeNardo DG.

Gut. 2019 May 10. pii: gutjnl-2018-317424. doi: 10.1136/gutjnl-2018-317424. [Epub ahead of print]

PMID:
31076405
3.

Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance.

Meyer MA, Baer JM, Knolhoff BL, Nywening TM, Panni RZ, Su X, Weilbaecher KN, Hawkins WG, Ma C, Fields RC, Linehan DC, Challen GA, Faccio R, Aft RL, DeNardo DG.

Nat Commun. 2018 Mar 28;9(1):1250. doi: 10.1038/s41467-018-03600-6.

4.

SNAIL1 action in tumor cells influences macrophage polarization and metastasis in breast cancer through altered GM-CSF secretion.

Brenot A, Knolhoff BL, DeNardo DG, Longmore GD.

Oncogenesis. 2018 Mar 29;7(3):32. doi: 10.1038/s41389-018-0042-x.

5.

Tissue-Resident Macrophages in Pancreatic Ductal Adenocarcinoma Originate from Embryonic Hematopoiesis and Promote Tumor Progression.

Zhu Y, Herndon JM, Sojka DK, Kim KW, Knolhoff BL, Zuo C, Cullinan DR, Luo J, Bearden AR, Lavine KJ, Yokoyama WM, Hawkins WG, Fields RC, Randolph GJ, DeNardo DG.

Immunity. 2017 Sep 19;47(3):597. doi: 10.1016/j.immuni.2017.08.018. No abstract available.

6.

Tissue-Resident Macrophages in Pancreatic Ductal Adenocarcinoma Originate from Embryonic Hematopoiesis and Promote Tumor Progression.

Zhu Y, Herndon JM, Sojka DK, Kim KW, Knolhoff BL, Zuo C, Cullinan DR, Luo J, Bearden AR, Lavine KJ, Yokoyama WM, Hawkins WG, Fields RC, Randolph GJ, DeNardo DG.

Immunity. 2017 Aug 15;47(2):323-338.e6. doi: 10.1016/j.immuni.2017.07.014. Erratum in: Immunity. 2017 Sep 19;47(3):597.

7.

Constitutive IRAK4 Activation Underlies Poor Prognosis and Chemoresistance in Pancreatic Ductal Adenocarcinoma.

Zhang D, Li L, Jiang H, Knolhoff BL, Lockhart AC, Wang-Gillam A, DeNardo DG, Ruzinova MB, Lim KH.

Clin Cancer Res. 2017 Apr 1;23(7):1748-1759. doi: 10.1158/1078-0432.CCR-16-1121. Epub 2016 Oct 4.

8.

Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy.

Jiang H, Hegde S, Knolhoff BL, Zhu Y, Herndon JM, Meyer MA, Nywening TM, Hawkins WG, Shapiro IM, Weaver DT, Pachter JA, Wang-Gillam A, DeNardo DG.

Nat Med. 2016 Aug;22(8):851-60. doi: 10.1038/nm.4123. Epub 2016 Jul 4.

9.

Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesis.

Ruhland MK, Loza AJ, Capietto AH, Luo X, Knolhoff BL, Flanagan KC, Belt BA, Alspach E, Leahy K, Luo J, Schaffer A, Edwards JR, Longmore G, Faccio R, DeNardo DG, Stewart SA.

Nat Commun. 2016 Jun 8;7:11762. doi: 10.1038/ncomms11762.

10.

Antagonizing Integrin ╬▓3 Increases Immunosuppression in Cancer.

Su X, Esser AK, Amend SR, Xiang J, Xu Y, Ross MH, Fox GC, Kobayashi T, Steri V, Roomp K, Fontana F, Hurchla MA, Knolhoff BL, Meyer MA, Morgan EA, Tomasson JC, Novack JS, Zou W, Faccio R, Novack DV, Robinson SD, Teitelbaum SL, DeNardo DG, Schneider JG, Weilbaecher KN.

Cancer Res. 2016 Jun 15;76(12):3484-95. doi: 10.1158/0008-5472.CAN-15-2663. Epub 2016 May 23.

11.

BH3-only proteins contribute to steatotic liver ischemia-reperfusion injury.

DuBray BJ Jr, Conzen KD, Upadhya GA, Gunter KL, Jia J, Knolhoff BL, Mohanakumar T, Chapman WC, Anderson CD.

J Surg Res. 2015 Apr;194(2):653-8. doi: 10.1016/j.jss.2014.10.024. Epub 2014 Oct 22.

12.

CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models.

Zhu Y, Knolhoff BL, Meyer MA, Nywening TM, West BL, Luo J, Wang-Gillam A, Goedegebuure SP, Linehan DC, DeNardo DG.

Cancer Res. 2014 Sep 15;74(18):5057-69. doi: 10.1158/0008-5472.CAN-13-3723. Epub 2014 Jul 31.

13.

Protective role of bortezomib in steatotic liver ischemia/reperfusion injury through abrogation of MMP activation and YKL-40 expression.

Tiriveedhi V, Upadhya GA, Busch RA, Gunter KL, Dines JN, Knolhoff BL, Jia J, Sarma NJ, Ramachandran S, Anderson CD, Mohanakumar T, Chapman WC.

Transpl Immunol. 2014 Mar;30(2-3):93-8. doi: 10.1016/j.trim.2013.12.003. Epub 2013 Dec 29.

PMID:
24380732
14.

Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses.

Mitchem JB, Brennan DJ, Knolhoff BL, Belt BA, Zhu Y, Sanford DE, Belaygorod L, Carpenter D, Collins L, Piwnica-Worms D, Hewitt S, Udupi GM, Gallagher WM, Wegner C, West BL, Wang-Gillam A, Goedegebuure P, Linehan DC, DeNardo DG.

Cancer Res. 2013 Feb 1;73(3):1128-41. doi: 10.1158/0008-5472.CAN-12-2731. Epub 2012 Dec 5.

15.

Novel in vitro model for studying hepatic ischemia-reperfusion injury using liver cubes.

DuBray BJ Jr, Conzen KD, Upadhya GA, Balachandran P, Jia J, Knolhoff BL, Alpers DH, Mohanakumar T, Chapman WC, Anderson CD.

Surgery. 2012 Aug;152(2):247-53. doi: 10.1016/j.surg.2012.02.012. Epub 2012 Jun 13.

Supplemental Content

Loading ...
Support Center